A comprehensive review published in World Journal of Pediatrics has synthesized decades of research to assign specific roles to CHD (chromodomain helicase DNA-binding) proteins during heart development. The study, led by a team from China, provides a working model that links CHD7, CHD4, and CHD8 to discrete stages of cardiac morphogenesis, offering a unifying framework to understand the origins of congenital heart defects.
The review systematically evaluated evidence from human genetics, animal models, and stem-cell systems. The findings reveal a division of labor among CHD proteins: CHD7 plays a dominant role in early heart structure formation, CHD3 and CHD4 act as 'identity guardians' during chamber formation, and CHD8 regulates later ventricular growth and functional maturation. Notably, CHD7 is the gene most frequently mutated in CHARGE syndrome, which includes heart defects as a key feature.
'The data show that we cannot treat these proteins as a single, interchangeable group. They have very distinct, stage‑specific jobs,' the authors said. 'For example, CHD7 is the key player in the early morphogenetic events that build the heart's structure, while CHD4 helps lock in the identity of heart cells as they differentiate.'
The study proposes three testable models—parallel, sequential, and compensatory—to guide future research on how these remodelers might coordinate or buffer each other's loss. This refined framework clarifies which gene to prioritize when studying specific heart defects and opens questions about interactions across developmental time.
The implications for clinical practice are direct. For genetic screening, the review provides clear priorities: CHD7 for outflow‑tract defects, CHD4 for chamber‑patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization can improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets.
Future studies combining time‑resolved multi‑omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies. The review was supported by multiple Chinese funding agencies, including the National Key Research and Development Program of China and the National Natural Science Foundation of China.
The full study is available at https://doi.org/10.1007/s12519-026-01049-y. For more information about the publishing journal, visit http://chuanlink-innovations.com.
